544 related articles for article (PubMed ID: 18546882)
21. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
J Rheumatol; 2001 Oct; 28(10):2294-7. PubMed ID: 11669172
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of refractory gout using combined therapy consisting of febuxostat and allopurinol in a patient with chronic renal failure.
Maekawa M; Tomida H; Aoki T; Hishida M; Morinaga T; Tamai H
Intern Med; 2014; 53(6):609-12. PubMed ID: 24633032
[TBL] [Abstract][Full Text] [Related]
23. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Wortmann RL; Macdonald PA; Hunt B; Jackson RL
Clin Ther; 2010 Dec; 32(14):2386-97. PubMed ID: 21353107
[TBL] [Abstract][Full Text] [Related]
24. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
Matzkies F
Med Klin (Munich); 1992 Sep; 87(9):460-2. PubMed ID: 1406482
[TBL] [Abstract][Full Text] [Related]
25. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
Perez-Ruiz F; Hernandez-Baldizon S; Herrero-Beites AM; Gonzalez-Gay MA
Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1299-305. PubMed ID: 20506124
[TBL] [Abstract][Full Text] [Related]
26. [A study of serum oxipurinol concentration and renal function in patients administered allopurinol].
Saji M
Nihon Jinzo Gakkai Shi; 1996 Dec; 38(12):640-50. PubMed ID: 9014485
[TBL] [Abstract][Full Text] [Related]
27. The optimal use of allopurinol: an audit of allopurinol use in South Auckland.
Stamp L; Gow P; Sharples K; Raill B
Aust N Z J Med; 2000 Oct; 30(5):567-72. PubMed ID: 11108066
[TBL] [Abstract][Full Text] [Related]
28. [Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses].
Mertz DP; Borner K
Med Welt; 1983 Sep; 34(36):974-9. PubMed ID: 6633222
[No Abstract] [Full Text] [Related]
29. [Effectiveness and tolerance of long-term uricosuric treatment].
Berg H
Z Gesamte Inn Med; 1990 Dec; 45(23):719-20. PubMed ID: 2102029
[TBL] [Abstract][Full Text] [Related]
30. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Becker MA; MacDonald PA; Hunt B; Gunawardhana L
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1011-7. PubMed ID: 22132950
[TBL] [Abstract][Full Text] [Related]
31. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
32. Difference of the plasma concentration and urinary excretion of allopurinol, oxypurinol, and purine bases between dietary intake and fasting.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
Int J Clin Pharmacol Ther; 1996 Apr; 34(4):157-62. PubMed ID: 8861734
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
34. Urate-lowering therapy for gout: focus on febuxostat.
Love BL; Barrons R; Veverka A; Snider KM
Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
[TBL] [Abstract][Full Text] [Related]
35. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.
Perez-Ruiz F; Calabozo M; Erauskin GG; Ruibal A; Herrero-Beites AM
Arthritis Rheum; 2002 Dec; 47(6):610-3. PubMed ID: 12522834
[TBL] [Abstract][Full Text] [Related]
36. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
[TBL] [Abstract][Full Text] [Related]
37. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.
Perez-Ruiz F; Calabozo M; Herrero-Beites AM; García-Erauskin G; Pijoan JI
Nephron; 2000 Nov; 86(3):287-91. PubMed ID: 11096285
[TBL] [Abstract][Full Text] [Related]
38. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
[TBL] [Abstract][Full Text] [Related]
39. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
[TBL] [Abstract][Full Text] [Related]
40. [Hyperuricemia and gout--treatment].
Gröbner W; Walter-Sack I
Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
